Target intelligence / Profile preview

Bile salt hydrolase (BSH)

Target
BSH
Molecular classification
Enzyme
01

Overview

Bile salt hydrolase (BSH; EC 3.5.1.24) is a bacterial enzyme widely expressed by the gut microbiota that catalyzes the deconjugation of glycine- or taurine-conjugated bile acids, representing the gateway reaction in microbial bile acid metabolism. By hydrolyzing the amide bond of conjugated bile acids, BSH generates unconjugated bile acids and free amino acids, which serve as substrates for downstream microbial modifications into secondary bile acids like deoxycholic acid (DCA) and lithocholic acid (LCA). This enzymatic activity significantly shapes the host bile acid pool, thereby modulating critical host signaling pathways mediated by bile acid receptors such as the farnesoid X receptor (FXR) and G protein-coupled bile acid receptor 1 (GPBAR1/TGR5). Dysregulation of BSH activity is strongly linked to metabolic and inflammatory disorders, including metabolic dysfunction-associated steatotic liver disease (MASLD), metabolic dysfunction-associated steatohepatitis (MASH), obesity, and type 2 diabetes. Pharmacological targeting of BSH using gut-restricted, small-molecule covalent inhibitors (such as GR-7 and AAA-10) or natural compounds (such as caffeic acid phenethyl ester) represents a promising microbiome-targeted therapeutic strategy. By suppressing BSH activity, these inhibitors increase the levels of conjugated bile acids, reduce cytotoxic secondary bile acids, improve intestinal barrier integrity, and alleviate hepatic steatosis and inflammation.

Other names
Choloylglycine hydrolaseConjugated bile acid hydrolaseCBAHBile salt hydrolases
02

Mechanism of action

Covalent or non-covalent inhibition of bacterial bile salt hydrolase (BSH) enzymes in the gut, preventing the deconjugation of primary bile acids and thereby reducing the formation of downstream cytotoxic secondary bile acids while preserving conjugated bile acids.

03

Biological functions

OtherImmune responseSignal transduction
04

Disease associations

InflammationOther
05

Safety considerations

Alteration of gut microbiota composition (dysbiosis)Impaired lipid and fat-soluble vitamin absorptionPotential systemic toxicity if the inhibitor is not gut-restrictedDisruption of host bile acid signaling pathways (FXR, TGR5)Reduced bacterial colonization resistance or survival in the gastrointestinal tract
06

Interacting drugs

GR-7

6 more in the full profile.

07

Biomarkers

Fecal bile salt hydrolase activityFecal bile acid levelsUnconjugated bile acid levelsSecondary bile acid levels (e.g., deoxycholic acid, lithocholic acid)Conjugated bile acid levels (e.g., tauro-beta-muricholic acid)

Beyond the preview

Go deeper on Bile salt hydrolase (BSH).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bile salt hydrolase (BSH).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call